 |
 |
Millenia Hope offers a new effective cure to the millions of people affected by malaria, and is developing SAR for compounds to treat AIDS, specifically targeting HIV-1 RNase H. We are diligently working to save the future generations of Africa and the World.
Company Profile
Millenia Hope Inc. is a biopharma company focused on comprehensive solutions to the problem of world disease. The company's objective is to fight disease through a portfolio of health products, developed by Millenia Hope and its team of clinical associates based around the world, focusing on parasitic diseases, particularly malaria, and AIDS and other infectious diseases.
Financial highlights
Publicly traded, Millenia Hope (Nasdaq OTCBB-MLHP) has spent approximately
$8 million U.S. on the development
of the MMH™ Malarex product line.
Millenia Hope BioPharma, its Canadian subsidiary, has spent over $30 million CAD (spent by the former Avance Pharma) on developing the worlds largest library of Phytomics (plant cell cultures) and their other products, specifically compounds to treat AIDS, targeting HIV-1 RNase H. The Company is seeking an institutional investment of
$25 million US to fund its ongoing drug discovery, invest in
new research and development facilities, and create
more efficient production methodologies at Millenia Hope Bio Pharma, the company’s Canadian
subsidiary, based in Montreal.
In 2005, the Company launched Malarex commercially in Africa by realizing its first two sales, in Guinea Conakry and Mali.
The Millenia Hope Foundation, based in the UK, is raising private funds to finance medications for those unable to pay for their treatments.
Investor Information Malarex is a new anti-parasite treatment in a $10 billion market where the World Health Organization has made new anti-malarial treatments a priority. |
|
CORPORATION FACT SHEET |
| FINANCIALS-SEC |
| CORPORATE COMMUNIQUÉ |
| INFORMATION REQUEST |
| INVESTOR RELATION CONTACTS |
Our Vision
To build a fully integrated biopharma
company that gives shareholders
value and provides hope in
the global fight against devastating
diseases, through the development of
innovative quality products that help
improve quality of life and promote
healthier lives.
Our Commitment
Providing hope
to Humanity
Millenia Hope is committed to the
patients and doctors for whom our
therapy is designed to ensure a
significant improvement over existing
medications.
Millenia Hope is committed to our
shareholders to create value by delivering
a fair and equitable return on their
investment.
Millenia Hope is commited to new drug discovery in the fields of Malaria and AIDS.
Millenia Hope is committed to those afflicted to act in a
socially responsible manner, by
providing broad access to effective
treatment.
Our commitment to our colleagues
and partners is to assist them to reach
their goals as they relate to our workplace
and corporate objectives.
Research & Development
Since its formation, the company has established excellent contacts among physicians, clinical
researchers and fundamental scientists, purchased the patent rights to an exciting new anti-malarial
agent, moved to acquire control of manufacturing facilities for MMH™ Malarex/MMH™ 18's raw
material and active ingredients, and commenced building a network of non-political organizations to
facilitate the distribution of the products in those regions where malaria is endemic.
Our research and development efforts continue to focus on the efficacy of our product, study the mode
of action, develop new formulations, pursue new molecular candidates and conduct clinical
studies. MMH™ Malarex/MMH™ 18 is in comformity with WHO guidelines, as per the new therapy ACT.
Millenia has entered the domain of AIDS research via the development of compounds to treat AIDS, specifically targeting HIV-1 RNase H.
|
Intellectual property (IP) As well, our IP portfolio contains the patent for use of compounds targeting HIV-1 RNase H. |
Business strategy Millenia Hope has obtained authorization to put MMH™ Malarex/MMH™ 18 on the market in 18 countries in Africa with 10 more pending. These countries, with the highest annual death rates from malaria. The Company has expanded its distribution network in order to facilitate the distribution of medications to reach the neediest regions of the world. In 2005, the Company launched MMH™ Malarex/MMH™ 18 commercially in Africa by realizing its first sales in Guinea Conakry and Mali. Millenia Hope is actively seeking alliances with nongovernmental organizations (NGO) in order for them to also support the distribution and reach the people who need help where they live. Those partnerships include educational programs to provide caregivers with effective home-based treatment (HBT) for malaria. |
